Retrospective Analysis of Second Primary Malignancies in Patients with Mycosis Fungoides and Sézary Syndrome in Croatia
Keywords:
mycosis fungoides, cutaneous T-cell lymphoma, breast cancer, folliculotropic mycosis fungoides, Hematological malignancy, malignancyAbstract
Introduction: Patients with mycosis fungoides (MF) have a higher risk of developing second primary malignancy. The type of second malignancy varies across the studies, and no established guidelines currently exist for screening MF patients.
Objective: To identify MF and Sézary syndrome (SS) patients at a potentially higher risk of developing a secondary primary malignancy, assess the prevalence of other secondary malignancies, and evaluate whether MF with other primary malignancies leads to a worse prognosis based on MF variants.
Methods: This observational single-center retrospective study followed 84 patients for a minimum of five years.
Results: We identified 16 patients (19%) with second malignancy, of whom eight (50%) had hematological neoplasms. Among other malignancies, breast cancer was the most common (N=5), followed by other malignancies, including lung cancer, prostate cancer, kidney cancer, and so on. The median age at disease onset was 53.0 years, while median age at second malignancy diagnosis was 60.5 years. No sex predominance was observed. Although not statistically significant, seven of sixteen patients (43.75%) who developed second malignancy had MF variant (such as folliculotropic MF) or Sezary syndrome. Disease progression was more common in patients with MF variant.
Conclusion: A higher risk for developing a second primary neoplasm was observed. However, additional cancer screening beyond routine age- and sex-appropriate examinations is not yet included in the current guidelines. Based on our findings, we recommend that MF patients undergo regular preventive screenings for the early detection of other primary malignancies.
References
Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator. Clin Dermatol. 2019;37(3):255–267. DOI:10.1016/j.clindermatol.2019.01.004. PMID: 31178107.
Väkevä L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol. 2000;115(1):62–65. DOI:10.1046/j.1523-1747.2000.00011.x. PMID: 10886509.
Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sézary syndrome: Evidence from population-based and clinical cohorts. Arch Dermatol.2007;143(1):45–50. DOI:10.1001/archderm.143.1.45. PMID: 17224541.
Brownell I, Etzel CJ, Yang DJ, et al. Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma. 2008;8(2):100–105. DOI:10.3816/CLM.2008.n.011.
Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol.1984;10(2):197–204. DOI:10.1016/S0190-9622(84)70023-5.
Kim YJ, Shin HJ, Won CH, et al. The incidence of other primary cancers in patients with cutaneous lymphoma. Ann Dermatol. 2018;30(3):335–341. DOI:10.5021/ad.2018.30.3.335.
Goyal A, O’Leary D, Goyal K, et al. Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer. J Am Acad Dermatol. 2021;85(6):1418–1428. DOI:10.1016/j.jaad.2020.06.1033. PMID: 32822803.
Kantor AF, Curtis RE, Vonderheid EC, et al. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer.1989;63(8):1612–1615. DOI:10.1002/1097-0142(19890415)63:8<1612::AID-CNCR2820630828>3.0.CO;2-C.
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the ISCL and the EORTC Cutaneous Lymphoma Task Force. Blood.2007;110(6):1713–1722. DOI:10.1182/blood-2007-03-055749. PMID: 17540844.
Petković M, Ilić I, Tončić RJ, et al. Mycosis fungoides with large cell transformation (CD30⁺) and B-cell chronic lymphocytic leukemia. Acta Dermatovenerol Croat. 2023;31(4):223–224.
Macagno N, Mastorino L, Rubatto M, et al. Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single-centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course. J Eur Acad Dermatol Venereol. 2022;36(12):2388-2392. DOI:10.1111/jdv.18469
Barzilai A, Trau H, David M, et al. Mycosis fungoides associated with B-cell malignancies. Br J Dermatol. 2006;155(2):379-386. DOI:10.1111/j.1365-2133.2006.07346.x. PMID: 16882178.
Hallermann C, Kaune MK, Tiemann M, et al. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol. 2007;86(7):509–515. DOI:10.1007/s00277-007-0304-2. PMID: 17403369.
Lindahl LM, Fenger-Grøn M, Iversen L. Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study. J Am Acad Dermatol.2014;71(3):529–535. DOI:10.1016/j.jaad.2014.03.044. PMID: 24931734.
Goyal A, O’Leary D, Goyal K, et al. Screening for second malignancies in mycosis fungoides: Non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma. J Eur Acad Dermatol Venereol.2021;35(9):1821–1829. DOI:10.1111/jdv.17384. PMID: 34013554.
Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: Validation of the revised ISCL/EORTC staging proposal. J Clin Oncol. 2010;28(31):4730–4739. DOI:10.1200/JCO.2010.28.31.4730. PMID: 21098385.
Published
Issue
Section
License
Copyright (c) 2025 Mikela Petkovic, Ivana Ilic, Romana Ceovic
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
